Pott-Hoeck C, Hiddemann W
Department of Hematology and Oncology, Georg-August University, Göttingen, Germany.
Ann Oncol. 1995 May;6(5):421-33. doi: 10.1093/oxfordjournals.annonc.a059209.
The purine analogs fludarabine (FAMP), 2-chlorodeoxy-adenosine (2-CDA) and 2-deoxycoformycin (DCF) comprise a novel group of agents with high activity in low-grade lymphoid malignancies. Although all three agents share several mechanisms of action, such as the induction of apoptosis, and toxic effects, such as prolonged immunosuppression, their activity appears to be different in different disorders. While FAMP and possibly also 2-CDA are highly active in chronic lymphocytic leukemia and low-grade follicular lymphomas, 2-CDA and DCF are most effective in hairy cell leukemia. However, prospective comparative evaluations are in progress and their results may ultimately help to define the appropriate indications for and potential side effects of these highly promising new agents.
嘌呤类似物氟达拉滨(FAMP)、2-氯脱氧腺苷(2-CDA)和2-脱氧助间型霉素(DCF)构成了一类新型药物,它们对低度恶性淋巴瘤具有高活性。尽管这三种药物具有一些共同的作用机制,如诱导细胞凋亡,以及一些共同的毒性作用,如长期免疫抑制,但它们在不同疾病中的活性似乎有所不同。FAMP以及可能还有2-CDA在慢性淋巴细胞白血病和低度滤泡性淋巴瘤中具有高活性,而2-CDA和DCF在毛细胞白血病中最有效。然而,前瞻性比较评估正在进行中,其结果最终可能有助于确定这些极具前景的新型药物的合适适应症和潜在副作用。